Navigation Links
Drug shows promise in prostate cancer spread to bone
Date:12/4/2012

ANN ARBOR, Mich. A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers.

About two-thirds of patients treated with cabozantinib had improvements on their bone scans, with 12 percent seeing complete resolution of uptake on bone scan. Bone scans assess the degree to which cancer is in the bone; improvements on these scans suggest a response to the drug.

"The effects of cabozantinib on bone scans are unprecedented in the treatment of prostate cancer," says lead study author David C. Smith, M.D., professor of internal medicine and urology at the University of Michigan Medical School.

Cabozantinib is designed to target two important pathways linked to the growth and spread of prostate cancer. The drug had the most effect on tumors that had spread to the bone, which is the major site where prostate cancer spreads. These tumors are typically very challenging to treat once they become resistant to hormone-based therapies.

In addition to the improvements on bone scans, 67 percent of patients with bone pain reported an improvement in pain control and 56 percent decreased or eliminated narcotic painkillers after treatment with cabozantinib. Results of the study appear in the Journal of Clinical Oncology.

The trial enrolled 171 men with castration-resistant prostate cancer, meaning their tumors no longer responded to hormone-based therapies. The study began as a randomized trial in which all patients received cabozantinib for 12 weeks, after which patients were randomized to receive continued cabozantinib or placebo. The randomization was stopped early because of the dramatic effects on bone scan, and because patients receiving placebo saw their cancer progress much more quickly than those that remained on drug.

Among the 31 patients who were randomized, cancer progressed after a median 23.9 weeks for patients taking cabozantinib, compared with 5.9 weeks for patients on placebo.

"Discontinuing randomization is not common. Stabilization of disease in advanced prostate cancer is rarely due to the natural history of the disease and is in this case due to drug effect," Smith says.

"While these initial results are promising, we are still uncertain how cabozantinib will impact the gold standard of survival," he adds.

Phase III studies have begun at some institutions, and U-M researchers are conducting a phase II study to better understand the effect cabozantinib has on bone. This drug is not offered routinely in clinical care at this time. For information about prostate cancer treatment options or clinical trials currently open at the U-M Comprehensive Cancer Center, call the Cancer AnswerLine at 800-865-1125.


'/>"/>
Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Genetic data shows that skin cancer risk includes more than UV exposure
2. Largest coronary artery disease study shows evidence of link between inflammation and heart disease
3. U-M study shows BPA exposure in fetal livers
4. Experimental Insomnia Drug Shows Promise
5. Young adults more likely to smoke cannabis than drink before driving, 2011 CAMH Monitor survey shows
6. Research from ASCOS Quality Care Symposium shows advances and challenges in improving the quality of cancer care
7. Most Women Who Choose Double Mastectomy Dont Need To, Study Shows
8. Imaging shows some brains compensate after traumatic injury
9. MRI shows brain disruption in patients with post-concussion syndrome
10. Huddersfield professors ground-breaking research shows just how well the 2012 Games were run
11. Networks it takes a village approach improves dementia care and informs research, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition ... at this week’s 2016 Europa Games Get Fit and Sports Expo in ... the Europa Orlando Expo coming up April 29-30, was selected as the perfect event ...
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... an invitation to those affected by a health insurance co-operative bankruptcy to ... proprietary process, individuals can receive over 1,500 FDA-approved prescription medications from over ...
(Date:4/28/2016)... ... April 28, 2016 , ... Today ... the Protocol Calendar Exchange , is officially open to all sponsors in ... available for sites to download into their clinical trial management system (CTMS), which ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... Chief Medical Officer at the Steadman Philippon Research Institute in Vail, Colorado, ... to raise awareness about the debilitating and costly musculoskeletal disorders that are ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016   Click here for ... Inc. (NYSE: DPLO), the nation,s largest independent specialty ... definitive agreement to acquire Valley Campus Pharmacy, Inc., ... a leading specialty pharmacy that provides individualized patient ... . In 2015, TNH generated approximately $400 ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
Breaking Medicine Technology: